The PLASMIC score is a recently described clinical scoring algorithm that rapidly assesses the probability of severe ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) deficiency among patients presenting with microangiopathic haemolytic anaemia. Using a large multi-institutional cohort, we explored whether an approach utilizing the PLASMIC score to risk-stratify patients with suspected immune thrombotic thrombocytopenic purpura (iTTP) could lead to significant cost savings. Our consortium consists of institutions with an unrestricted approach to ADAMTS13 testing (Group A) and those that require pre-approval by the transfusion medicine service (Group B). Institutions in Group A tested more patients than those in Group B (P < 0·001) but did not identify more cases of iTTP (P = 0·29) or have lower iTTP-related mortality (P = 0·84). Decision tree cost analysis showed that applying a PLASMIC score-based strategy to screen patients for ADAMTS13 testing in Group A would have reduced costs by approximately 27% over the 12-year period of our study compared to the current approach. Savings were primarily driven by a reduction in unnecessary therapeutic plasma exchanges, but lower utilization of ADAMTS13 testing and subspecialty consultations also contributed. Our data indicate that using the PLASMIC score to guide ADAMTS13 testing and the management of patients with suspected iTTP could be associated with significant cost savings.
Keywords: PLASMIC; TTP; ADAMTS13; cost savings/effectiveness; thrombotic thrombocytopenic purpura.
© 2019 British Society for Haematology and John Wiley & Sons Ltd.
Conflict of interest statement
Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study.Lancet Haematol. 2017 Apr;4(4):e157-e164. doi: 10.1016/S2352-3026(17)30026-1. Epub 2017 Mar 2. Lancet Haematol. 2017. PMID: 28259520
ADAMTS13 test and/or PLASMIC clinical score in management of acquired thrombotic thrombocytopenic purpura: a cost-effective analysis.Transfusion. 2017 Nov;57(11):2609-2618. doi: 10.1111/trf.14230. Epub 2017 Jun 23. Transfusion. 2017. PMID: 28646526 Free PMC article.
Validation of PLASMIC score and follow-up data in a cohort of patients with suspected microangiopathies from Southern Italy.J Thromb Thrombolysis. 2018 Aug;46(2):174-179. doi: 10.1007/s11239-018-1674-6. J Thromb Thrombolysis. 2018. PMID: 29737462 Clinical Trial.
Taking Empiricism out of Immune Thrombotic Thrombocytopenic Purpura: Current and Future Treatment Strategies.Transfus Med Rev. 2019 Oct;33(4):248-255. doi: 10.1016/j.tmrv.2019.06.005. Epub 2019 Aug 15. Transfus Med Rev. 2019. PMID: 31645275 Review.
When targeted therapies alleviate the burden of TPE: The example of immune-mediated TTP.Transfus Apher Sci. 2019 Jun;58(3):273-277. doi: 10.1016/j.transci.2019.04.012. Epub 2019 Apr 19. Transfus Apher Sci. 2019. PMID: 31018909 Review.